Pfizer has secured a $5.2billion acquisition of Anacor Pharmaceuticals which will enable the pharmaceutical giant to sell an eczema treatment that could reach up to $2billion in sales. Crisaborole, the anti-inflammatory tropical treatment created by Anacor, could serve over 30 million Americans as a first-line option after receiving approval from the FDA. The deal is expected to be finalised in 2016 and is not set to affect Pfizer's the third quarter fiscal guidance.
Pfizer has secured a $5.2billion acquisition of Anacor Pharmaceuticals which will enable the pharmaceutical giant to sell an eczema treatment that could reach up to $2billion in sales. Crisaborole, the anti-inflammatory tropical treatment created by Anacor, could serve over 30 million Americans as a first-line option after receiving approval from the FDA. The deal is expected to be finalised in the third quarter and is not set to affect Pfizer's 2016 fiscal guidance.